Exercise of 974,365 Y warrants resulting in the issuance of 389,746 new ordinary shares and 389,746 Z warrants
Berlin, Germany, January 23, 2024, 6:00 p.m. CET – TME Pharma NV (Euronext Growth Paris: ALTME), a biotechnology company specializing in the development of novel therapies for the treatment of cancer by targeting the tumor microenvironment (TME), provides an update update of the number of ordinary shares, Y share subscription warrants and Z share subscription warrants in circulation following the exercise of 974,365 Y share subscription warrants for €97,436.50 as of price of the completion of the first exercise period of the Y Share Subscription Warrants.